![]() | Thomas J SlagaDepartment of Pharmacology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX | Department of Pharmacology, The University of Texas ... |
KOL Resume for Thomas J Slaga
Year | |
---|---|
2020 | Department of Pharmacology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX |
2019 | Department of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas |
2018 | Department of Pharmacology, UT Health Science Center San Antonio, San Antonio, Texas |
2017 | Department of Pharmacology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA |
2016 | Department of Pharmacology, The University of Texas Health Science Center San Antonio, 7703 Floyd Curl Drive, 78229, San Antonio, TX, USA |
2015 | Department of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas. |
2014 | Department of Pharmacology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA |
2013 | The Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA University of Texas Health Science Center at San Antonio Graduate School of Biomedical Sciences San Antonio Texas |
2012 | Department of Pharmacology, Medical Research Division, Edinburg-Regional Academic Health Center, The University of Texas Health Science Center at San Antonio , Edinburg, TX 78541, USA , |
2010 | the Departments of Pharmacology, University of Texas, San Antonio, Texas |
2009 | Department of Pharmacology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229 |
2008 | AMC Cancer Research Center, Lakewood, Colorado |
2007 | Department of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA |
2004 | Department of Cancer Causation and Prevention, AMC Cancer Research Center, Denver, Colorado 80214 and the University of Colorado Comprehensive Cancer Center, Denver, Colorado 80045 AMC Cancer Research Center, Denver, CO |
2003 | Center for Cancer Causation and Prevention, AMC Cancer Research Center and University of Colorado Comprehensive Cancer Center, Denver, CO 80214, USA |
2002 | AMC Cancer Research Center, 80214, Lakewood, Colorado, CO, USA |
2001 | AMC Cancer Research Center, 1600 Pierce St., Denver, Colorado Center for Cancer Causation and Prevention, American Medical Center Cancer Research Center, Denver, CO 80214; |
2000 | AMC Cancer Research Center, Denver, Colorado, 80214, USA |
1999 | Center for Cancer Causation and Prevention, AMC Cancer Research Center, Denver, Colorado, 80214 |
1998 | M.D. Anderson Cancer Center, Science Park-Research Division, The University of Texas, P.O. Box 389, Smithville, Texas, 78957 AMC Cancer Research Center, 1600 Pierce Street, Lakewood, CO 80214, USA |
1997 | Department of Carcinogenesis, The University of Texas M. D. Anderson Cancer Center, Science Park–Research Division, Smithville, Texas |
1996 | Department of Carcinogenesis, University of Texas M. D. Anderson Cancer Center, Science Park−Research Division, Smithville, Texas 78957, Lankenau Medical Research Center, 100 Lancaster Avenue West of City Line, Wynnewood, Pennsylvania 19096, and Ben May Institute, University of Chicago, Chicago, Illinois 60637 |
1995 | M.D. Anderson Cancer Center, Science Park - Research Division, The University of Texas, 78757, Smithville, TX, USA |
1994 | University of Texas, M.D. Anderson Cancer Center, Science Park, Research Division, Smithville, TX, USA |
1993 | University of Texas System Cancer Center, Science Park Research Division, P.O. Box 389, Smithville, TX 78957, USA |
1992 | University of Texas M.D. Anderson Cancer Center, Science Park-Research Division, Smithville 78957. |
1991 | Programme of Multistage Carcinogenesis, International Agency for Research on Cancer, Lyon, France. Department of Carcinogenesis, Science Park-Research Division, The University of Texas M.D.Anderson Cancer CenterPO Box 389, Smithville, TX 78957, USA The University of Texas M.D. Anderson Cancer Center, Science Park-Research Division, Smithville, Texas 78957 U.S.A. |
1990 | Department of Carcinogenesis, Science Park‐Research Division, The University of Texas System M.D. Anderson Cancer Center, Smithville, Texas |
1989 | Department of Carcinogenesis, The University of Texas M. D. Anderson Cancer Center, Smithville, Texas |
1988 | Science Park, The University of Texas M. D. Anderson Cancer Center, Smithville, Texas |
1987 | The University of Texas System Cancer Center, Science Park-Research Division, Smithville, TX 78957 U.S.A. |
1986 | University of Texas System Cancer Center, Science Park-Research Division, Smithville, TX USA |
1985 | The University of Texas System Cancer Center, Science Park-Research DivisionPO Box 389, Smithville, TX 78957 |
1984 | Director, Biochemist and Professor of Biochemistry, Ph.D. The University of Texas System Cancer Center Research Division Science Park P.O. Drawer 389 Smithville Texas 78957 U.S.A. |
1983 | Biology Division, Oak Ridge National Laboratory, 37830, Oak Ridge, TN, USA University of Texas System Cancer, Center Science Park-Research Division, Smithville, Texas |
1982 | University of Tennessee‐Oak Ridge Graduate School of Biomedical Sciences, Tennessee 37830 Biology Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee, U.S.A. |
1981 | Biology Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee |
Thomas J Slaga: Influence Statistics
Concept | World rank |
---|---|
cell 3pc | #1 |
3hmc interaction | #1 |
tumorigenesis mouse skin | #1 |
res survival chloroquine | #1 |
nmol 712 | #1 |
twostage promotion | #1 |
v79 fluoro | #1 |
2 mezerein | #1 |
tumor promoter agent | #1 |
constitutive activation ikk | #1 |
ru24782 sencar mice | #1 |
cells abnormal epidermis | #1 |
tumorpromotion protocol | #1 |
skin tpa | #1 |
14fold h2b | #1 |
expression cx311 | #1 |
receptor phorbol diesters | #1 |
antiinflammatory cytokine bap | #1 |
syndmbadedna adducts method | #1 |
progression phase model | #1 |
akt nfkappab pathway | #1 |
hyperplastic agent | #1 |
micrococcal nuclease dinucleosomes | #1 |
viability mouse melanoma | #1 |
ru24782 | #1 |
bja cyclopentafused derivative | #1 |
cholesterol bacteria | #1 |
repeated tumor experiments | #1 |
species multistage process | #1 |
data 506 chemicals | #1 |
promotion skin | #1 |
peroxides skin | #1 |
inhibition mouse epidermis | #1 |
dmi grmediated transcription | #1 |
cyclopentafused derivatives benzaanthracene | #1 |
mnng ethylnitrosourea | #1 |
ru24782 neoplastic cyclooxygenase | #1 |
dermis hair follicles | #1 |
active bacterial cell | #1 |
mc microsomal metabolizing | #1 |
coke oven materials | #1 |
comparative study stocks | #1 |
pah diolepoxide reacting | #1 |
mezerein dmba | #1 |
species differences aspects | #1 |
3nearest neighbor | #1 |
5′oh region | #1 |
mice sencar | #1 |
micrograms mouse | #1 |
nfκb component | #1 |
Open the FULL List in Excel | |
Prominent publications by Thomas J Slaga
Skin tumors can be effectively induced in mice by the repetitive application of a carcinogen. The relative order of sensitivity to complete carcinogenesis is Sencar > CD-1 > C57BL/6 ≥ BALB/c ≥ ICR/Ha Swiss > C3H. Skin tumors in mice can also be induced by the sequential application of a sub-threshold dose of a carcinogen (initiation phase) followed by repetitive treatment with a weak or noncarcinogenic tumor promoter (promotion phase). The relative order of sensitivity to ...
Known for Mouse Skin | Multistage Carcinogenesis | Promotion Tpa | C57bl 6 | Dark Basal Keratinocytes |
The mouse skin carcinogenesis protocol is a unique model for understanding the molecular events leading to oncogenic transformation. Mutations in the Ha-ras gene, and the presence of functional cyclin D1 and the EGF receptor, have proven to be important in this system. However, the signal transduction pathways connecting these elements during mouse skin carcinogenesis are poorly understood. This paper studies the relevance of the Akt and ERK pathways in the different stages of chemically ...
Known for Mouse Skin | Akt Signaling | Neoplastic Genes | Protein Kinase | Mice Mice |
Binding of [20-3H]phorbol 12,13-dibutyrate ([3H]PDB) to intact human promyelocytic leukemia cells susceptible (HL-60) or resistant (R-35) to phorbol ester-induced differentiation was characterized. Specific binding of [3H]PDB to both HL-60 and R-35 cells at 37 degrees C reached a maximum within 15-20 min. Maximal specific [3H]PDB binding to HL-60 cells was followed by a decline (down regulation) of radioactivity. This down regulation was temperature dependent, because no loss of ...
Known for Specific Binding | Leukemia Cells | Phorbol Ester | 37 Degrees | Induced Differentiation |
The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells.
[ PUBLICATION ]
Rel/NF-kappaB transcription factors are implicated in the control of cell proliferation, apoptosis and transformation. The key to NF-kappaB regulation is the inhibitory IkappaB proteins. During response to diverse stimuli, IkappaBs are rapidly phosphorylated by IkappaB kinases (IKKs), ubiquitinated and undergo degradation. We have investigated the expression and function of NF-kappaB, IkappaB inhibitors and IKKs in normal prostate epithelial cells and prostate carcinoma (PC) cell lines ...
Known for Constitutive Activation | Prostate Carcinoma | Kappab Transcription | Neoplastic Genes | Androgen Independent |
Effect of Combined Treatment with Ursolic Acid and Resveratrol on Skin Tumor Promotion by 12-O-Tetradecanoylphorbol-13-Acetate
[ PUBLICATION ]
In this study, the effects of combining ursolic acid + resveratrol, for possible combined inhibitory effects on skin tumor promotion, were evaluated. Ursolic acid, resveratrol, and the combination of ursolic acid + resveratrol were applied topically prior to 12-O-tetracanoylphorbol-13-acetate (TPA) treatment on mouse skin to examine their effect on TPA-induced signaling pathways, epidermal hyperproliferation, skin inflammation, inflammatory gene expression, and skin tumor promotion. The ...
Known for Ursolic Acid | Skin Tumor | Greater Extent | Individual Compounds | Acetate Tpa |
Studies on the mechanism of skin tumor promotion: Evidence for several stages in promotion
[ PUBLICATION ]
The effects of nonpromoting and weakly promoting diterpenes on skin tumor promotion by 12-O-tetradecanoylphorbol 13-acetate (TPA) were investigated. When phorbol and phorbol 12,13-diacetate (both nonpromoting) were given simultaneously with TPA after 7,12-dimethylbenz[a]-anthracene (DMBA) initiation in female mice, they had no effect on TPA promotion. However, the nonpromoter 4-O-methyl-TPA and the weak promoter mezerein were found to inhibit TPA promotion in a dose-dependent manner when ...
Known for Skin Tumor Promotion | Tpa Mezerein | 2 Weeks | Female Mice | Stage Promoter |
Studies on mechanism of action of anti-tumor-promoting agents: their specificity in two-stage promotion
[ PUBLICATION ]
The effects of fluocinolone acetonide (FA), retinoic acid (RA), and tosylphenylalanine chloromethyl ketone (TPCK) on two-stage promotion after 7,12-dimethylbenz[a]-anthracene (DMBA) initiation in female Sencar mice were investigated. The two-stage promotion protocol was achieved by twice weekly applications of 2 microgram of 12-O-tetradecanoylphorbol 13-acetate (TPA) for 2 weeks (stage I) followed by twice weekly applications of mezerein for 18 weeks (stage II). Separately stage I and II ...
Known for Stage Promotion | Potent Inhibitor | Dark Basal Keratinocytes | Fluocinolone Acetonide | Weekly Applications |
Gap junctional intercellular communication (GJIC) of cultured mouse epidermal cells is mediated by a gap junction protein, connexin 43, and is dependent on the calcium concentration in the medium, with higher GJIC in a high-calcium (1.2 mM) medium. In several mouse epidermal cell lines, we found a good correlation between the level of GJIC and that of immunohistochemical staining of E-cadherin, a calcium-dependent cell adhesion molecule, at cell-cell contact areas. The variant cell line ...
Known for Mouse Epidermal Cells | Intercellular Communication | Connexin 43 | Cadherin Gjic | Gap Junctional |
2‐methoxyestradiol blocks cell‐cycle progression at G2/M phase and inhibits growth of human prostate cancer cells
[ PUBLICATION ]
2-Methoxyestradiol (2-ME), an endogenous metabolite of 17beta-estradiol, is present in human blood and urine. Here we show for the first time that 2-ME significantly inhibited the growth of normal prostate epithelial cells and androgen-dependent LNCaP and androgen-independent DU145 prostate cancer cells. This growth inhibition was accompanied by a twofold increase in the G(2)/M population, with a concomitant decrease in the G(1) population, as shown by cell-cycle analysis. 2-ME treatment ...
Known for Prostate Cancer | G2 Phase | 2me Treatment | Cell Cycle | Protein P53 |
Polyamine levels were evaluated in human HL-60 promyelocytic leukemia cells after treatment with inducers of terminal differentiation. Differentiation in these cells was determined by increases in the percentage of morphologically mature cells and in lysozyme activity. Treatment of the HL-60 cells with phorbol 12-myristate-13-acetate (PMA), phorbol 12,13-didecanoate or other inducers of terminal differentiation such as dimethylsulfoxide and retinoic acid resulted in increased levels of ...
Known for Polyamine Levels | Leukemia Cells | Phorbol Diesters | Pma Treatment | Putrescine Spermidine |
Phorbol esters stimulate DNA synthesis and ornithine decarboxylase activity in mouse epidermal cell cultures
[ PUBLICATION ]
TUMOUR-PROMOTING agents have been defined by their ability to promote tumour formation on carcinogen-initiated mouse skin. The most potent of these agents are the diesters of phorbol which are the active components of croton oil, the classic promoting substance. Phorbol esters can be chemically modified in a number of positions to form molecules with a wide range of promoter potency1. Such modifications have been useful in determining structure-function relationships2. A good correlation ...
Known for Phorbol Esters | Dna Synthesis | Decarboxylase Activity | Mouse Epidermal | Cell Cultures |
Key People For Mouse Skin
Thomas J Slaga:Expert Impact
Concepts for whichThomas J Slagahas direct influence:Mouse skin, Sencar mice, Tumor promotion, Skin tumor, Ursolic acid, Skin tumors, Epidermal cells, Acetic acid.
Thomas J Slaga:KOL impact
Concepts related to the work of other authors for whichfor which Thomas J Slaga has influence:Mouse skin, Protein kinase, Prostate cancer, Stem cells, Tumor promotion, Cell proliferation, Gap junctions.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |